European Commission's 2009 priorities address anticounterfeiting, legislative recast and Eudamed
This article was originally published in SRA
Executive Summary
The European Commission’s priorities for the medtech sector in 2009 include following up on a study on medical device counterfeiting and parallel trade that it conducted last year, and working on the recast of the medical device directives1,2.
You may also be interested in...
WHO To Clean Up Data Integrity Failings
The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date.
EU Regulators Prioritize Nitrosamine Evaluations Deadline
EU regulators say that sponsors must complete their nitrosamine-related risk evaluations for all EU medicines containing chemically-synthesised active substances within the six-month timeframe.
Sticking To Nitrosamine Evaluations Deadline Is Priority For EU Regulators
EU regulators say that sponsors must complete their nitrosamine-related risk evaluations for all EU medicines containing chemically-synthesised active substances within the six-month timeframe.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: